Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 Jun 29;16(1):179. doi: 10.1186/s12967-018-1552-1.

2.

TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study.

Juratli TA, Stasik S, Zolal A, Schuster C, Richter S, Daubner D, Juratli MA, Thowe R, Hennig S, Makina M, Meinhardt M, Lautenschlaeger T, Schackert G, Krex D, Thiede C.

Clin Cancer Res. 2018 Jun 25. doi: 10.1158/1078-0432.CCR-17-3717. [Epub ahead of print]

PMID:
29941484
3.

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6. Erratum in: J Transl Med. 2018 Jun 29;16(1):179.

4.

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1581-1589. doi: 10.1007/s00432-018-2671-z. Epub 2018 May 28.

PMID:
29808316
5.

Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas.

Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, Williams EA, Martinez-Lage M, Soucek S, Robel K, Penson T, Krause M, Appold S, Meinhardt M, Pinzer T, Miller JJ, Krex D, Ely HA, Silverman IM, Christiansen J, Schackert G, Wakimoto H, Kirsch M, Brastianos PK, Cahill DP.

Oncotarget. 2017 Nov 24;8(65):109228-109237. doi: 10.18632/oncotarget.22650. eCollection 2017 Dec 12.

6.

Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the IDH1 Mutation Status.

Uckermann O, Juratli TA, Galli R, Conde M, Wiedemuth R, Krex D, Geiger K, Temme A, Schackert G, Koch E, Steiner G, Kirsch M.

Clin Cancer Res. 2018 Jun 1;24(11):2530-2538. doi: 10.1158/1078-0432.CCR-17-1795. Epub 2017 Dec 19.

PMID:
29259030
7.

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204.

PMID:
29121274
8.

Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.

Kessler T, Sahm F, Sadik A, Stichel D, Hertenstein A, Reifenberger G, Zacher A, Sabel M, Tabatabai G, Steinbach J, Sure U, Krex D, Grosu AL, Bewerunge-Hudler M, Jones D, Pfister SM, Weller M, Opitz C, Bendszus M, von Deimling A, Platten M, Wick W.

Neuro Oncol. 2018 Feb 19;20(3):367-379. doi: 10.1093/neuonc/nox160.

PMID:
29016808
9.

Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.

Klein J, Juratli TA, Radev Y, Daubner D, Soucek S, Schackert G, Krex D.

Oncology. 2017;93(1):43-50. doi: 10.1159/000464464. Epub 2017 Apr 11.

PMID:
28395288
10.

Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.

Abou-El-Ardat K, Seifert M, Becker K, Eisenreich S, Lehmann M, Hackmann K, Rump A, Meijer G, Carvalho B, Temme A, Schackert G, Schröck E, Krex D, Klink B.

Neuro Oncol. 2017 Apr 1;19(4):546-557. doi: 10.1093/neuonc/now231.

11.

Chemotherapy for intracranial ependymoma in adults.

Gramatzki D, Roth P, Felsberg J, Hofer S, Rushing EJ, Hentschel B, Westphal M, Krex D, Simon M, Schnell O, Wick W, Reifenberger G, Weller M.

BMC Cancer. 2016 Apr 23;16:287. doi: 10.1186/s12885-016-2323-0.

12.

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M.

J Clin Oncol. 2016 May 10;34(14):1611-9. doi: 10.1200/JCO.2015.63.4691. Epub 2016 Mar 14.

PMID:
26976423
13.

Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.

Zolal A, Juratli TA, Linn J, Podlesek D, Sitoci Ficici KH, Kitzler HH, Schackert G, Sobottka SB, Rieger B, Krex D.

J Neurooncol. 2016 May;127(3):551-7. doi: 10.1007/s11060-016-2063-7. Epub 2016 Jan 30.

PMID:
26830088
14.

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.

Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, Di Tacchio M, Sommer K, Baumgarten P, Bähr O, Steinbach JP, Trojan J, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Braun C, Schittenhelm J, Frueh JT, Ullrich E, Mittelbronn M, Plate KH, Reiss Y.

EMBO Mol Med. 2016 Jan 1;8(1):39-57. doi: 10.15252/emmm.201505505.

15.

Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.

Ringel F, Pape H, Sabel M, Krex D, Bock HC, Misch M, Weyerbrock A, Westermaier T, Senft C, Schucht P, Meyer B, Simon M; SN1 study group.

Neuro Oncol. 2016 Jan;18(1):96-104. doi: 10.1093/neuonc/nov145. Epub 2015 Aug 4.

16.

Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.

Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D.

J Neurooncol. 2015 Sep;124(2):197-205. doi: 10.1007/s11060-015-1822-1. Epub 2015 Jun 2.

PMID:
26033545
17.

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G.

Acta Neuropathol. 2015 May;129(5):679-93. doi: 10.1007/s00401-015-1409-0. Epub 2015 Mar 18.

18.

RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.

Mezzanotte JJ, Hill V, Schmidt ML, Shinawi T, Tommasi S, Krex D, Schackert G, Pfeifer GP, Latif F, Clark GJ.

Epigenetics. 2014 Nov;9(11):1496-503. doi: 10.4161/15592294.2014.983361.

19.

Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas.

Hill VK, Shinawi T, Ricketts CJ, Krex D, Schackert G, Bauer J, Wei W, Cruickshank G, Maher ER, Latif F.

BMC Cancer. 2014 Jul 10;14:506. doi: 10.1186/1471-2407-14-506.

20.

Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.

Eisele G, Wick A, Eisele AC, Clément PM, Tonn J, Tabatabai G, Ochsenbein A, Schlegel U, Neyns B, Krex D, Simon M, Nikkhah G, Picard M, Stupp R, Wick W, Weller M.

J Neurooncol. 2014 Mar;117(1):141-5. doi: 10.1007/s11060-014-1365-x. Epub 2014 Jan 19.

21.

Is there pseudoprogression in secondary glioblastomas?

Juratli TA, Engellandt K, Lautenschlaeger T, Geiger KD, von Kummer R, Cerhova J, Chakravarti A, Krex D, Schackert G.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1094-9. doi: 10.1016/j.ijrobp.2013.09.036.

22.

Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing.

Eisenreich S, Abou-El-Ardat K, Szafranski K, Campos Valenzuela JA, Rump A, Nigro JM, Bjerkvig R, Gerlach EM, Hackmann K, Schröck E, Krex D, Kaderali L, Schackert G, Platzer M, Klink B.

PLoS One. 2013 Sep 27;8(9):e76623. doi: 10.1371/journal.pone.0076623. eCollection 2013.

23.

End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey.

Heese O, Vogeler E, Martens T, Schnell O, Tonn JC, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkhah G, Sabel M, Steiger HJ, Schlegel U, Löffler M, Weller M, Westphal M; German Glioma Network.

Neuro Oncol. 2013 Sep;15(9):1251-6. doi: 10.1093/neuonc/not089. Epub 2013 Jun 28.

24.

Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.

Juratli TA, Schackert G, Krex D.

Pharmacol Ther. 2013 Sep;139(3):341-58. doi: 10.1016/j.pharmthera.2013.05.003. Epub 2013 May 18. Review.

PMID:
23694764
25.

Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.

Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D.

Neuro Oncol. 2013 Jun;15(6):682-90. doi: 10.1093/neuonc/not006. Epub 2013 Feb 14.

26.

DNA methylation profiles of long- and short-term glioblastoma survivors.

Shinawi T, Hill VK, Krex D, Schackert G, Gentle D, Morris MR, Wei W, Cruickshank G, Maher ER, Latif F.

Epigenetics. 2013 Feb;8(2):149-56. doi: 10.4161/epi.23398. Epub 2013 Jan 4.

27.

A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network.

Seidel C, Hentschel B, Simon M, Schnell O, Heese O, Tatagiba M, Krex D, Reithmeier T, Kowoll A, Weller M, Wick W.

J Neurol. 2013 Mar;260(3):847-55. doi: 10.1007/s00415-012-6718-9. Epub 2012 Oct 27.

28.

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.

Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schackert G, Krex D.

J Neurooncol. 2012 Dec;110(3):325-33. doi: 10.1007/s11060-012-0977-2. Epub 2012 Sep 27. Erratum in: J Neurooncol. 2013 Jan;111(1):95. Schrok, E [corrected to Schrock, E].

PMID:
23015095
29.

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.

Juratli TA, Kirsch M, Robel K, Soucek S, Geiger K, von Kummer R, Schackert G, Krex D.

J Neurooncol. 2012 Jul;108(3):403-10. doi: 10.1007/s11060-012-0844-1. Epub 2012 Mar 13.

PMID:
22410704
30.

Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk.

Yasuno K, Bakırcıoğlu M, Low SK, Bilgüvar K, Gaál E, Ruigrok YM, Niemelä M, Hata A, Bijlenga P, Kasuya H, Jääskeläinen JE, Krex D, Auburger G, Simon M, Krischek B, Ozturk AK, Mane S, Rinkel GJ, Steinmetz H, Hernesniemi J, Schaller K, Zembutsu H, Inoue I, Palotie A, Cambien F, Nakamura Y, Lifton RP, Günel M.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19707-12. doi: 10.1073/pnas.1117137108. Epub 2011 Nov 21.

31.

5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.

Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, Schackert G, Krex D, Lu Q, Pfeifer GP.

Cancer Res. 2011 Dec 15;71(24):7360-5. doi: 10.1158/0008-5472.CAN-11-2023. Epub 2011 Nov 3.

32.

Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.

Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, Bostroem A, Heese O, Koelbl O, Garbe C, Schadendorf D; Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma.

Cancer. 2011 Apr 15;117(8):1697-703. doi: 10.1002/cncr.25631. Epub 2010 Nov 8.

33.

Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors.

Barbus S, Tews B, Karra D, Hahn M, Radlwimmer B, Delhomme N, Hartmann C, Felsberg J, Krex D, Schackert G, Martinez R, Reifenberger G, Lichter P.

J Natl Cancer Inst. 2011 Apr 6;103(7):598-606. doi: 10.1093/jnci/djr036. Epub 2011 Feb 23.

PMID:
21346226
34.

RET-protooncogene variants in patients with sporadic neoplasms of the digestive tract and the central nervous system.

Rückert F, Görgens H, Richter I, Krex D, Schackert G, Kuhlisch E, Fitze G, Saeger HD, Pilarsky C, Grützmann R, Schackert HK.

Int J Colorectal Dis. 2011 Jul;26(7):835-40. doi: 10.1007/s00384-011-1150-7. Epub 2011 Feb 11.

PMID:
21311890
35.

Frequent epigenetic inactivation of KIBRA, an upstream member of the Salvador/Warts/Hippo (SWH) tumor suppressor network, is associated with specific genetic event in B-cell acute lymphocytic leukemia.

Hill VK, Dunwell TL, Catchpoole D, Krex D, Brini AT, Griffiths M, Craddock C, Maher ER, Latif F.

Epigenetics. 2011 Mar;6(3):326-32. Epub 2011 Mar 1.

36.

Complementary therapy use in patients with glioma: an observational study.

Heese O, Schmidt M, Nickel S, Berger H, Goldbrunner R, Tonn JC, Bähr O, Steinbach JP, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkhah G, Löffler M, Weller M, Westphal M; German Glioma Network.

Neurology. 2010 Dec 14;75(24):2229-35. doi: 10.1212/WNL.0b013e31820202c6.

PMID:
21172846
37.

Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis.

Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, Morris M, Gentle D, Chalmers AD, Maher ER, Latif F.

Oncogene. 2011 Feb 24;30(8):978-89. doi: 10.1038/onc.2010.471. Epub 2010 Oct 18.

PMID:
20956940
38.

Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.

Stummer W, Nestler U, Stockhammer F, Krex D, Kern BC, Mehdorn HM, Vince GH, Pichlmeier U.

J Neurooncol. 2011 Jun;103(2):361-70. doi: 10.1007/s11060-010-0400-9. Epub 2010 Oct 5.

PMID:
20922459
39.

Rosette-forming glioneuronal tumor of the fourth ventricle in an elderly patient.

Podlesek D, Geiger K, Hendry DJ, Schackert G, Krex D.

J Neurooncol. 2011 Jul;103(3):727-31. doi: 10.1007/s11060-010-0408-1. Epub 2010 Sep 25.

PMID:
20865299
40.

Postoperative cerebellar mutism in adult patients with Lhermitte-Duclos disease.

Afshar-Oromieh A, Linhart H, Podlesek D, Schrempf W, Schackert G, Krex D.

Neurosurg Rev. 2010 Oct;33(4):401-8. doi: 10.1007/s10143-010-0278-1. Epub 2010 Jul 29. Review.

PMID:
20668902
41.

Genome-wide association study of intracranial aneurysm identifies three new risk loci.

Yasuno K, Bilguvar K, Bijlenga P, Low SK, Krischek B, Auburger G, Simon M, Krex D, Arlier Z, Nayak N, Ruigrok YM, Niemelä M, Tajima A, von und zu Fraunberg M, Dóczi T, Wirjatijasa F, Hata A, Blasco J, Oszvald A, Kasuya H, Zilani G, Schoch B, Singh P, Stüer C, Risselada R, Beck J, Sola T, Ricciardi F, Aromaa A, Illig T, Schreiber S, van Duijn CM, van den Berg LH, Perret C, Proust C, Roder C, Ozturk AK, Gaál E, Berg D, Geisen C, Friedrich CM, Summers P, Frangi AF, State MW, Wichmann HE, Breteler MM, Wijmenga C, Mane S, Peltonen L, Elio V, Sturkenboom MC, Lawford P, Byrne J, Macho J, Sandalcioglu EI, Meyer B, Raabe A, Steinmetz H, Rüfenacht D, Jääskeläinen JE, Hernesniemi J, Rinkel GJ, Zembutsu H, Inoue I, Palotie A, Cambien F, Nakamura Y, Lifton RP, Günel M.

Nat Genet. 2010 May;42(5):420-5. doi: 10.1038/ng.563. Epub 2010 Apr 4.

42.

CpG island hypermethylation in human astrocytomas.

Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, Pfeifer GP.

Cancer Res. 2010 Apr 1;70(7):2718-27. doi: 10.1158/0008-5472.CAN-09-3631. Epub 2010 Mar 16.

43.

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M.

J Clin Oncol. 2009 Dec 1;27(34):5743-50. doi: 10.1200/JCO.2009.23.0805. Epub 2009 Oct 5.

44.

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.

Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C, Sieder C, Sorenson G, Parker R, Nikolova Z.

J Neurooncol. 2010 Feb;96(3):393-402. doi: 10.1007/s11060-009-9976-3. Epub 2009 Aug 18.

PMID:
19688297
45.

Do platelets stored in additive solution really show limited osmotic balance?

Ringwald J, Krex D, Weiss D, Hendelmeier M, Zingsem J, Eckstein R.

Transfusion. 2009 Mar;49(3):605-7; author reply 607-8. doi: 10.1111/j.1537-2995.2008.02049.x. No abstract available.

PMID:
19243551
46.

Epigenetic markers in human gliomas: prospects for therapeutic intervention.

Hesson LB, Krex D, Latif F.

Expert Rev Neurother. 2008 Oct;8(10):1475-96. doi: 10.1586/14737175.8.10.1475. Review.

PMID:
18928342
47.

Polymorphisms of homocysteine metabolism are associated with intracranial aneurysms.

Semmler A, Linnebank M, Krex D, Götz A, Moskau S, Ziegler A, Simon M.

Cerebrovasc Dis. 2008;26(4):425-9. doi: 10.1159/000155638. Epub 2008 Sep 18.

PMID:
18799873
48.

[Analysis of tissue inhibitor of metalloproteinase-2 gene polymorphisms in a caucasian population with abdominal aortic aneurysms].

Hinterseher I, Krex D, Kuhlisch E, Pilarsky C, Schneiders W, Saeger HD, Bergert H.

Zentralbl Chir. 2008 Aug;133(4):332-7. doi: 10.1055/s-2008-1076862. German.

PMID:
18702016
49.

A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.

Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D.

Ann Oncol. 2009 Jan;20(1):175-81. doi: 10.1093/annonc/mdn548. Epub 2008 Aug 7.

PMID:
18687982
50.

The stem cell marker prominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel approaches for studying central nervous system disease.

Huttner HB, Janich P, Köhrmann M, Jászai J, Siebzehnrubl F, Blümcke I, Suttorp M, Gahr M, Kuhnt D, Nimsky C, Krex D, Schackert G, Löwenbrück K, Reichmann H, Jüttler E, Hacke W, Schellinger PD, Schwab S, Wilsch-Bräuninger M, Marzesco AM, Corbeil D.

Stem Cells. 2008 Mar;26(3):698-705. Epub 2007 Dec 20.

Supplemental Content

Support Center